Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986920 | 0.77 | TAAR1 (0.34) | TAAR1CYP3A4ALDH1A1TSHRTDP1 | |
| SCHEMBL111658 | 0.76 | TAAR1 (0.47) | TAAR1DPP4GAACYP3A4ALDH1A1 | |
| SCHEMBL24122316 | 0.75 | ACHE (0.44) | TAAR1GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7997992 | 0.74 | TAAR1 (0.41) | TAAR1GAACYP3A4ALDH1A1TSHR | |
| SCHEMBL8370064 | 0.74 | TAAR1 (0.41) | TAAR1GAACYP3A4ALDH1A1TSHR | |
| SCHEMBL1374604 | 0.74 | TAAR1 (0.45) | TAAR1GAACYP3A4ALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL3451387 | 0.72 | TAAR1 (0.39) | TAAR1GAACYP3A4ALDH1A1TSHR | |
| SCHEMBL24399067 | 0.72 | GABRA1 (0.48) | TAAR1DPP4CYP3A4ALDH1A1TSHR | |
| Bromide SCHEMBL8150313 | 0.72 | SNCA (0.38) | TAAR1CYP3A4ALDH1A1TSHRTDP1 | |
| SCHEMBL18698097 | 0.71 | KMT2A (0.44) | GAAALDH1A1TSHRTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958865-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-02 | — | — | US | disclosed |
| EP-4126861-B1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AG (DE) | 2025-06-18 | — | — | EP | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3700904-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3700904-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20230064983-A1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-01 | — | — | US | disclosed |
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3958865-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2021198020-A1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-07 | — | — | WO | disclosed |
| WO-2020216774-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216774-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-3700904-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | Bayer AG (DE) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064983-A1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | TAAR1 2388/4885DPP4 2155/4885GAA 1655/4885 |
| US-20220378762-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | EGFR, ERBB2, ERBB4 | TAAR1 3250/4885DPP4 3489/4885GAA 3295/4885 |
| US-12403135-B2 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | EGFR, ERBB2, ERBB4 | TAAR1 3250/4885DPP4 3489/4885GAA 3295/4885 |
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | CYP4B1, CYP2C19, CYP3A4 | TAAR1 3919/4885DPP4 307/4885GAA 331/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | TAAR1 1133/4885DPP4 2444/4885GAA 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.